-- MAフィナンシャル・グループ（ASX:MAF）は、火曜日にオーストラリア証券取引所に提出した書類の中で、第1四半期の運用資産総額（AUM）が前年同期比44%増の148億豪ドルに達したと発表した。 総AUMは3月31日までの四半期で3%減少したが、これは主に以前から発表されていたマリオン・ショッピングセンターの売却手続きによるもので、同社は2026年の収益への影響は軽微と見込んでいる。 同社によると、機関投資家を含む総資金流入額は4億9,000万豪ドルで、前年同期の7億7,900万豪ドルから減少した。 また、提出書類によると、フィンシュアが管理する融資残高は2月28日までの1年間で27%増加し、1,790億豪ドルに達した。3月の月間融資申請総額は過去最高の110億豪ドルを記録した。
Related Articles
Asia
Huadian New Energy 2025 Profit Down 18%, Revenue Up 15%
Huadian New Energy (SHA:600930) posted 2025 attributable net profit of 7.26 billion yuan, down 18% from 8.83 billion yuan the previous year.Earnings per share slipped to 0.18 yuan from 0.24 yuan, according to a filing with the Shanghai bourse.Operating revenue rose 15% year over year to 39.0 billion yuan from 34.0 billion yuan.Shares of the power company were down 1% in recent trade.
$SHA:600930
Asia
National Storage REIT Says New South Wales Court Approves Brookfield, GIC Takeover Scheme
National Storage REIT (ASX:NSR) confirmed that the Supreme Court of New South Wales has approved the share scheme of arrangement and granted judicial advice for the trust scheme, enabling a Brookfield Funds and GIC-led consortium to proceed with the acquisition of all the company stapled securities, according to a Tuesday Australian bourse filing.The schemes are now legally effective following lodgment with the Australian Securities and Investments Commission, and the company's securities are expected to be suspended from trading at the close of trading on Tuesday, per the filing.The scheme record date is April 29, with implementation scheduled for May 8, when security holders will receive the scheme consideration, the filing added.
$ASX:NSR
Asia
Starpharma Says US FDA Supports First-in-Human Study of Cancer Radiotherapy Candidate; Shares Gain 7%
Starpharma Holdings (ASX:SPL) has received positive feedback from the US Food and Drug Administration (FDA) on the proposed design of its first-in-human phase 1 clinical study of the DEP HER2 radiotherapy candidate, according to a Tuesday filing with the Australian bourse.The company is developing the candidate to treat certain gastric/gastro-oesophageal junction cancers and other advanced cancers in patients who have previously received targeted therapy.The US FDA feedback supports plans to launch the phase one study, which is on track to begin in the second half of the year.The FDA also confirmed that the radiotherapy candidate is targeting a population with a significant unmet medical need, indicating the potential for a fast-track designation or other accelerated development pathways, Starpharma said.The company's shares were 7% higher in recent Tuesday trade.
$ASX:SPL